Egalet Ltd.
Efficacy and Safety of Egalet-002 in Patients With Moderate-to-Severe Chronic Low Back Pain
- Conditions
- Moderate-to-severe Chronic Low Back Pain
- Interventions
- Drug: Placebo of oxycodone extended-release
- First Posted Date
- 2016-03-23
- Last Posted Date
- 2018-03-05
- Lead Sponsor
- Egalet Ltd
- Target Recruit Count
- 549
- Registration Number
- NCT02716857
- Locations
- ๐บ๐ธ
Site 245, Boise, Idaho, United States
๐บ๐ธSite 251, Spartanburg, South Carolina, United States
๐บ๐ธSite 226, Boston, Massachusetts, United States
Safety and Tolerability of Egalet-002 in Patients With Moderate-to-Severe Chronic Noncancer Pain
- Conditions
- Moderate-to-severe Chronic Noncancer Pain
- Interventions
- First Posted Date
- 2015-11-13
- Last Posted Date
- 2018-03-05
- Lead Sponsor
- Egalet Ltd
- Target Recruit Count
- 281
- Registration Number
- NCT02603705
- Locations
- ๐บ๐ธ
Site 320, Plantation, Florida, United States
๐บ๐ธSite 347, Kettering, Ohio, United States
๐บ๐ธSite 330, Dallas, Texas, United States
SPRIX in 0 to 11 Year-Old Patients Undergoing Open Surgical Procedures
- First Posted Date
- 2014-04-03
- Last Posted Date
- 2017-03-17
- Lead Sponsor
- Egalet Ltd
- Target Recruit Count
- 45
- Registration Number
- NCT02102516
- Locations
- ๐ต๐ฑ
Instytut "Centrum Zdrowia Matki Polki" (Institute "Mother's Memorial Hospital"), Lodz, Poland
๐ต๐ฑKlinika Chirurgii i Traumatologii Dzieciecej - Dzieciecy Szpital Kliniczny im. prof. Antoniego Gebali, Lublin, Poland
๐ต๐ฑRegional Hospital of Ludwika Rydygiera in Torun, Torun, Poland
Study to Assess the Absorption and Tolerability of Intranasal Ketorolac Tromethamine and to Assess the Effects of Oxymetazoline Hydrochloride and Fluticasone Propionate on the Absorption and Tolerability of Intranasal Ketorolac Tromethamine in Participants With Allergic Rhinitis
- Conditions
- Allergic Rhinitis
- Interventions
- First Posted Date
- 2011-06-03
- Last Posted Date
- 2018-03-06
- Lead Sponsor
- Egalet Ltd
- Target Recruit Count
- 24
- Registration Number
- NCT01365650
- Locations
- ๐ฆ๐บ
Pain and Anaesthesia Research Clinic/Royal Adelaide Hospital, Adelaide, Australia
Open Label Study to Assess the Pharmacokinetics of Intranasal Ketorolac Tromethamine Following Fluticasone Propionate in Healthy Subjects
- Conditions
- Healthy Subjects
- Interventions
- First Posted Date
- 2011-06-03
- Last Posted Date
- 2017-03-15
- Lead Sponsor
- Egalet Ltd
- Target Recruit Count
- 36
- Registration Number
- NCT01365611
- Locations
- ๐ฌ๐ง
ICON Development Solutions, Manchester, United Kingdom
The Pharmacokinetics of Ketorolac Tromethamine Administered Intranasally (IN) for Postoperative Pain in Children Aged 12 Through 17 Years
- First Posted Date
- 2011-06-01
- Last Posted Date
- 2017-03-16
- Lead Sponsor
- Egalet Ltd
- Target Recruit Count
- 20
- Registration Number
- NCT01363076
- Locations
- ๐บ๐ธ
Stanford University Medical Center, Stanford, California, United States
Study to Assess the PK of Ketorolac Tromethamine Intranasal and to Assess the Effects of a Oxymetazoline Hydrochloride on the PK of Ketorolac Tromethamine
- Conditions
- Assess Pharmacokinetics of Ketorolac Tromethamine Intranasal and Assess Effects of a Oxymetazoline Hydrochloride on the PK of Ketorolac Tromethamine
- Interventions
- First Posted Date
- 2011-06-01
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Egalet Ltd
- Target Recruit Count
- 21
- Registration Number
- NCT01363089
- Locations
- ๐ฌ๐ง
ICON Development Solutions, Manchester, United Kingdom
Study to Determine the Tolerability, Safety and Pharmacokinetics of Ketorolac Tromethamine by Intranasal Administration in Healthy Volunteers
- First Posted Date
- 2011-06-01
- Last Posted Date
- 2017-03-16
- Lead Sponsor
- Egalet Ltd
- Target Recruit Count
- 15
- Registration Number
- NCT01363050
- Locations
- ๐ฌ๐ง
Medeval Limited, Manchester, United Kingdom
Study of the Tolerability of Ketorolac Tromethamine Following Intranasal Administration in Healthy Volunteers
- First Posted Date
- 2011-06-01
- Last Posted Date
- 2018-03-06
- Lead Sponsor
- Egalet Ltd
- Target Recruit Count
- 40
- Registration Number
- NCT01363063
- Locations
- ๐ฌ๐ง
ICON Developmental Solutions, Manchester, United Kingdom
Assessment of Nasal Deposition and Clearance of Ketorolac Solution Administered Using the Valois Nasal Spray Device
- First Posted Date
- 2011-05-19
- Last Posted Date
- 2017-02-08
- Lead Sponsor
- Egalet Ltd
- Target Recruit Count
- 13
- Registration Number
- NCT01356212
- Locations
- ๐ฌ๐ง
Pharmaceutical Profiles, Ltd, Ruddington, Nottingham, United Kingdom